Physician profile
Erik Hamill
NPI 1326496589
$4,612.45
in general payments reported to CMS, 2019-2025
24 companies · $1,560 in 2025
The $1,560 reported for 2025 was more than what 87% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,098 · 2024: $1,955 · 2025: $1,560.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,612.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,612.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,094.22 | 2023-2025 | |
| Ironshore Pharmaceuticals INC. | $449.33 | 2023-2024 | Jornay Pm |
| Lundbeck LLC | $430.63 | 2023-2025 | Rexulti |
| Corium, LLC | $419.81 | 2023-2025 | Azstarys |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $384.99 | 2023-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $274.16 | 2023-2025 | Rexulti, Abilify Mycite, Abilify Maintena |
| Axsome Therapeutics, INC. | $217.85 | 2023-2025 | Auvelity |
| Alkermes, INC. | $162.64 | 2023-2025 | Aristada, Lybalvi |
| Vanda Pharmaceuticals INC. | $148.10 | 2023-2025 | Fanapt, Hetlioz |
| Janssen Pharmaceuticals, INC | $138.03 | 2023-2025 | Spravato |
| Vertical Pharmaceuticals, LLC | $132.61 | 2024-2025 | Relexxii |
| Supernus Pharmaceuticals, INC. | $128.23 | 2024-2025 | Qelbree |
| Collegium Pharmaceutical, INC. | $96.63 | 2025 | Jornay Pm |
| Teva Pharmaceuticals USA, INC. | $91.26 | 2023-2025 | Austedo Xr, Austedo Xr |
| Almatica Pharma LLC | $63.98 | 2024-2025 | Loreev Xr |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $60.06 | 2024-2025 | Cobenfy |
| Noven Therapeutics, LLC | $56.59 | 2024 | Xelstrym, Secuado |
| Avion Pharmaceuticals | $56.29 | 2023 | Methylphenidate Hydrochloride |
| Bausch Health US, LLC | $51.15 | 2024-2025 | Aplenzin |
| Tris Pharma INC | $48.22 | 2023-2024 | Dyanavel Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $46.27 | 2023-2025 | Trintellix |
| Neos Therapeutics, LP | $32.48 | 2024-2025 | Adzenys Xr-Odt |
| Livanova USA, INC. | $16.20 | 2024 | Vns Therapy Symmetry Model 8103 Generator |
| Biogen, INC. | $12.72 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erik Hamill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.